A Phase 3 interventional study of Ranibizumab 0.5mg and Ranibizumab 0.5 mg in Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM), sponsored by Novartis Pharmaceuticals. Completed at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-24.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 6th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 36th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 457 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
29 studies in Choroidal Neovascularization by Novartis: none open now, none under way, none of them phase 3. Of 29 finished, 22 (76%) have results posted.
Among the 29 studies in Choroidal Neovascularization by Novartis, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2013, is one of 14 in phase 3, and was the 18th registered.
Novartis’s Choroidal Neovascularization studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 29 in Choroidal Neovascularization:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)
This was a phase III, multi-center, randomized, double-masked, active-controlled study comparing 0.5 mg ranibizumab vs. vPDT therapy. The study included 15 scheduled visits over 12 months, and there were to be two additional visits (2a, 3a) for subset of patients in whom PK analysis were performed.
There were 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients entered the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria were met and were randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or Group III vPDT (randomization ratio of 2:2:1) and received first treatment of either a ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the clinical center within 7 days to undergo safety assessments as well as assessments of the effect of treatment by the evaluating investigator. The following visits were performed at one month intervals starting at Visit 4 and continuing through Visit 14. At all monthly visits (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for group III) the decision for treatment were made by the evaluating investigator based on the VA stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at all following monthly visits for all three groups one of the three options can recommended by evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT. The treating investigator were then perform treatment based on randomization and masking requirements.
At each monthly visit, patients had a safety evaluation by the evaluating investigator prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations and evaluation of adverse events and vital signs. Routine hematology, chemistry, and urinalysis profiles were obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12 several procedures and assessments were performed which are required at study completion visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 mg ranibizumab driven by visual acuity stability criteria
Drug: Ranibizumab 0.5mg
0.5 mg ranibizumab driven by disease activity criteria
Drug: Ranibizumab 0.5 mg
verteporfin PDT
Drug: Verteporfin PDT
0.5 mg ranibizumab (intravitreal injections)
Also known as: Lucentis
0.5 mg ranibizumab (intravitreal injections)
Also known as: Lucentis
Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
Also known as: Visudyne
Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3
Best corrected visual acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.
Time frame: From Baseline to Month 3
Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6
Best corrected visual acuity (BCVA) was tested using the early treatment diabetic retinopathy study (ETDRS) VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 6.
Time frame: From Baseline to Month 6
The Average Change in BCVA Score From Baseline to Month 1 Through Month 12
Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 12
Time frame: From Baseline to Month 12
Mean Change From Baseline in Visual Acuity Over Time
Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.
Time frame: Change from baseline at months 3, 6, and 12
Categorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye
ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.
Time frame: From Baseline to Month 12
Mean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)
Central sub-field thickness (CSFT) is a variable assessed via Optical Coherence Tomography (OCT). OCT was performed prior to any study drug administration to assess presence of intra, subretinal fluid, or increase of CSFT.
Time frame: Baseline, Month 3, Month 6, and Month 12
Number of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12
CNV leakage is assessed via fluorescein angiography (center involvement) category: definite, questionable, absent, can't grade, and missing.
Time frame: From Baseline until Month 12
NEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12
The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.
Time frame: Change from baseline at month 3, 6 and 12
Number of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups
To assess treatment pattern with ranibizumab
Time frame: From Baseline to Month 12
Randomized Set: consisted of all randomized patients. Patients were considered randomized when they had been given a randomization number.
| Milestone | Group I | Group II | Group III |
|---|---|---|---|
| Started | 182 | 184 | 91 |
| Completed | 173 | 175 | 83 |
| Not completed | 9 | 9 | 8 |
| Withdrew: Withdrawal by subject | 7 | 3 | 7 |
| Withdrew: Physician decision | 0 | 2 | 1 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 2 | 0 |
Best corrected visual acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.
| ETDRS letters | Group I | Group II | Group III |
|---|---|---|---|
| Baseline | 53.7 ± 12.65 | 54.2 ± 13.01 | 52.6 ± 12.29 |
| Average Month 1 to Month 3 | 63.1 ± 12.80 | 63.9 ± 13.28 | 57.1 ± 13.21 |
Best corrected visual acuity (BCVA) was tested using the early treatment diabetic retinopathy study (ETDRS) VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 6.
| ETDRS letters | Group I | Group II | Group III |
|---|---|---|---|
| Baseline | 53.7 ± 12.65 | 54.2 ± 13.01 | 52.6 ± 12.29 |
| Average Month 1 to Month 6 | 64.1 ± 12.77 | 64.9 ± 13.14 | 59.6 ± 12.99 |
Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 12
| ETDRS letters | Group I | Group II | Group III |
|---|---|---|---|
| Baseline | 53.7 ± 12.65 | 54.2 ± 13.01 | 52.6 ± 12.29 |
| Average Month 1 to Month 12 | 64.8 ± 12.82 | 65.9 ± 13.26 | 61.2 ± 13.10 |
Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.
| ETDRS letters | Group I | Group II | Group III |
|---|---|---|---|
| Month 3 | 10.5 ± 9.13 | 10.8 ± 10.09 | 4.5 ± 9.35 |
| Month 6 | 11.6 ± 10.66 | 12.1 ± 11.57 | 9.5 ± 10.50 |
| Month 12 | 12.0 ± 11.50 | 13.1 ± 11.46 | 10.3 ± 12.69 |
ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.
| Participants | Group I | Group II | Group III |
|---|---|---|---|
| Gained≥15 letters or reached 84 letters-Month 3 | 58 | 59 | 15 |
| Gained≥10 letters or reached 84 letters-Month 3 | 97 | 107 | 24 |
| Gained≥15 letters or reached 84 letters-Month 6 | 71 | 73 | NA |
| Gained≥10 letters or reached 84 letters-Month 6 | 100 | 121 | NA |
| Gained≥15 letters or reached 84 letters-Month 12 | 81 | 75 | NA |
| Gained≥10 letters or reached 84 letters-Month 12 | 110 | 115 | NA |
Central sub-field thickness (CSFT) is a variable assessed via Optical Coherence Tomography (OCT). OCT was performed prior to any study drug administration to assess presence of intra, subretinal fluid, or increase of CSFT.
| micrometer | Group I | Group II | Group III |
|---|---|---|---|
| Month 3 | -66.4 ± 98.68 | -71.2 ± 81.28 | -29.1 ± 75.57 |
| Month 6 | -70.7 ± 73.20 | -75.1 ± 80.90 | -59.3 ± 81.82 |
| Month 12 | -79.4 ± 71.39 | -80.8 ± 85.93 | -66.0 ± 93.60 |
CNV leakage is assessed via fluorescein angiography (center involvement) category: definite, questionable, absent, can't grade, and missing.
| Participants | Group I | Group II | Group III |
|---|---|---|---|
| Baseline - Definite | 164 | 160 | 76 |
| Baseline - Questionable | 1 | 3 | 0 |
| Baseline - Absent | 14 | 19 | 13 |
| Baseline - Can't Grade | 2 | 0 | 0 |
| Baseline - Missing | 1 | 2 | 2 |
| Month 12 - Definite | 34 | 43 | 26 |
| Month 12 - Questionable | 6 | 4 | 2 |
| Month 12 - Absent | 133 | 129 | 56 |
| Month 12 - Can't Grade | 2 | 2 | 0 |
| Month 12 - Missing | 7 | 6 | 7 |
The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.
| Composite score | Group I | Group II | Group III |
|---|---|---|---|
| Month 3 | 4.7 ± 12.28 | 6.1 ± 13.49 | 1.7 ± 13.55 |
| Month 6 | 5.0 ± 13.40 | 5.6 ± 15.42 | -0.1 ± 15.30 |
| Month 12 | 4.4 ± 16.03 | 4.7 ± 16.92 | 1.3 ± 16.85 |
To assess treatment pattern with ranibizumab
| Injections | Group I | Group II | Group III With 0.5mg Ranibizumab | Group III Without 0.5mg Ranibizumab |
|---|---|---|---|---|
| Month 3 | 2.4 ± 0.53 | 2.1 ± 0.84 | NA ± NA | NA ± NA |
| Month 12 | 4.6 ± 2.44 | 3.9 ± 2.50 | 3.2 ± 2.25 | 3.8 ± 2.36 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Treatment, approximately 4 years.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group I | — | 7/182 (3.8%) | 102/182 (56%) |
| Group II | — | 15/185 (8.1%) | 116/185 (62.7%) |
| Group III With 0.5mg Ranibizumab | — | 8/75 (10.7%) | 50/75 (66.7%) |
| Group III Without 0.5mg Ranibizumab | — | 0/14 (0%) | 8/14 (57.1%) |
| Event | Group I | Group II | Group III With 0.5mg Ranibizumab | Group III Without 0.5mg Ranibizumab |
|---|---|---|---|---|
| ArrhythmiaCardiac disorders | 0/182 | 0/185 | 1/75 | 0/14 |
| Coronary artery diseaseCardiac disorders | 0/182 | 1/185 | 1/75 | 0/14 |
| Retinal detachment (Fellow eye)Eye disorders | 0/182 | 1/185 | 1/75 | 0/14 |
| Rectal polypGastrointestinal disorders | 0/182 | 0/185 | 1/75 | 0/14 |
| AppendicitisInfections and infestations | 0/182 | 0/185 | 1/75 | 0/14 |
| Endophthalmitis (Study eye)Infections and infestations | 0/182 | 0/185 | 1/75 | 0/14 |
| Physical examination abnormalInvestigations | 0/182 | 0/185 | 1/75 | 0/14 |
| Shock hypoglycaemicMetabolism and nutrition disorders | 0/182 | 0/185 | 1/75 | 0/14 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/182 | 0/185 | 1/75 | 0/14 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/182 | 0/185 | 1/75 | 0/14 |
| Event | Group I | Group II | Group III With 0.5mg Ranibizumab | Group III Without 0.5mg Ranibizumab |
|---|---|---|---|---|
| Retinal haemorrhage (Fellow eye)Eye disorders | 2/182 | 4/185 | 0/75 | 2/14 |
| NasopharyngitisInfections and infestations | 17/182 | 20/185 | 8/75 | 1/14 |
| Upper respiratory tract infectionInfections and infestations | 14/182 | 12/185 | 6/75 | 0/14 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 8/182 | 14/185 | 2/75 | 0/14 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/182 | 0/185 | 1/75 | 1/14 |
| PalpitationsCardiac disorders | 1/182 | 0/185 | 0/75 | 1/14 |
| Choroidal neovascularisation (Fellow eye)Eye disorders | 2/182 | 3/185 | 1/75 | 1/14 |
| Conjunctivitis allergic (Fellow eye)Eye disorders | 0/182 | 1/185 | 1/75 | 1/14 |
| Conjunctivitis allergic (Study eye)Eye disorders | 1/182 | 2/185 | 1/75 | 1/14 |
| Dry eye (Fellow eye)Eye disorders | 2/182 | 2/185 | 0/75 | 1/14 |
Randomized Set: consisted of all randomized patients. Patients were considered randomized when they had been given a randomization number.
| Age, Continuous(Years) | Group I | Group II | Group III | Total |
|---|---|---|---|---|
| Mean | 52.0 ± 12.01 | 51.5 ± 12.13 | 49.1 ± 14.81 | 51.2 ± 12.68 |
| Sex: Female, Male(Participants) | Group I | Group II | Group III | Total |
|---|---|---|---|---|
| Female | 128 | 116 | 67 | 311 |
| Male | 54 | 68 | 24 | 146 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Sep 2013 to primary completion in Sep 2016, 36 months.
Results were first posted in Jun 2019, 2 years 9 months after primary completion.
Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 35. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →